ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

被引：0
|
作者：
Sands, Jacob
Mandrekar, Sumithra J.
Oxnard, Geoffrey R.
Kozono, David E.
Hillman, Shauna L.
Dahlberg, Suzanne Eleanor
Sun, Zhuoxin
Chaft, Jamie E.
Govindan, Ramaswamy
Gerber, David E.
Gray, Jhanelle Elaine
Malik, Shakun M.
Mooney, Margaret M.
Janne, Pasi A.
Vokes, Everett E.
Kelly, Karen
Ramalingam, Suresh S.
Stinchcombe, Tom
机构：
[1] Lahey Hosp & Med Ctr, Boston, MA USA
[2] Mayo Clin, Rochester, MN USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] IBCSG Stat Ctr, Boston, MA USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[8] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[9] NCI, Rockville, MD USA
[10] Univ Chicago Med, Dept Med, Sect Hematol Oncol, Chicago, IL USA
[11] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA
[12] Emory Univ Hosp, Winship Canc Inst, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[13] Duke Canc Inst, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9077
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Effect of antimicrobial therapy on progression free survival of immunotherapy and chemo-/ immunotherapy in patients with NSCLC.
    Uhlenbruch, M.
    Krueger, S.
    PNEUMOLOGIE, 2024, 78 : S97 - S98
  • [42] MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.
    Therasse, P.
    Vansteenkiste, J. F.
    Zielinski, M.
    De Pas, T. M.
    Atanackovic, D.
    Sequist, L. V.
    Vallieres, E.
    Swisher, S.
    Adams, S.
    Passlick, B.
    Eberhardt, W. E. E.
    Grunenwald, D.
    Mok, T.
    Boyer, M.
    Katz, A.
    Douillard, J.
    Debois, M.
    Brichard, V. G.
    Altorki, N. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma
    Van Anh Trinh
    Zobniw, Chrystia
    Hwu, Wen-Jen
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (08) : 933 - 940
  • [44] Intensified Adjuvant Treatment for High-Risk Resected Cutaneous Angiosarcoma of the Head and Neck
    El Shatanofy, Muhammad
    Thakkar, Punam
    Patel, Vishal
    Joshi, Arjun
    Goodman, Joseph
    Siegel, Robert
    Haroun, Faysal
    Ojong-Ntui, Martin
    Goyal, Sharad
    Bauman, Julie
    Rao, Yuan James
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2023, 169 (05) : 1225 - 1233
  • [45] Capecitabine as Maintenance Therapy for High-Risk, Resected Colorectal Cancer
    Auber, Miklos L.
    Wen, Sijin
    Hobbs, Gerald
    Higa, Gerald M.
    GASTROINTESTINAL TUMORS, 2021, 8 (02) : 81 - 86
  • [46] Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence
    Hindson, Jordan
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2024, 21 (03) : 141 - 141
  • [47] Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence
    Jordan Hindson
    Nature Reviews Gastroenterology & Hepatology, 2024, 21 : 141 - 141
  • [48] Adjuvant therapy for high-risk medulloblastoma: more is better?
    Strother, Douglas
    Lafay-Cousin, Lucie
    NEURO-ONCOLOGY, 2021, 23 (07) : 1048 - 1049
  • [49] Systemic adjuvant therapy for patients with high-risk melanoma
    Tsai, Kenneth Y.
    ARCHIVES OF DERMATOLOGY, 2007, 143 (06) : 779 - 782
  • [50] Adjuvant therapy for women with high-risk endometrial carcinoma
    Dowdy, Sean C.
    Glaser, Gretchen E.
    LANCET ONCOLOGY, 2018, 19 (03): : 268 - 269
12345